BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P. Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases. Prog Med Chem 2009;48:81-131. [PMID: 21544958 DOI: 10.1016/s0079-6468(09)04803-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem 2011;18:2686-714. [PMID: 21649578 DOI: 10.2174/092986711796011229] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 7.7] [Reference Citation Analysis]
2 Jain S, Jain PK, Sain S, Kishore D, Dwivedi J. Anticancer s-Triazine Derivatives: A Synthetic Attribute. MROC 2020;17:904-21. [DOI: 10.2174/1570193x17666200131111851] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vanhaesebroeck B, Vogt PK, Rommel C. PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol 2010;347:1-19. [PMID: 20549473 DOI: 10.1007/82_2010_65] [Cited by in Crossref: 15] [Cited by in F6Publishing: 37] [Article Influence: 1.4] [Reference Citation Analysis]